贾晓妮,高艺,陈建波,等.奥氮平治疗精神分裂症的临床疗效及影响因素分析[J].安徽医药,2021,25(11):2317-2320. |
奥氮平治疗精神分裂症的临床疗效及影响因素分析 |
Clinical efficacy and analysis of influencing factors of olanzapine in the treatment of schizo? phrenia |
|
DOI:10.3969/j.issn.1009-6469.2021.11.047 |
中文关键词: 精神分裂症 奥氮平 临床疗效 影响因素 |
英文关键词: Schizophrenia Olanzapine Clinical efficacy Influencing factors |
基金项目:西安市科技计划项目[201805099YX7SF33(3)、 201805099YX7SF33(4)];西安市卫生健康委员会科研项目( J201801004) |
|
摘要点击次数: 1678 |
全文下载次数: 693 |
中文摘要: |
目的统计奥氮平治疗精神分裂症的疗效和不良反应情况,对奥氮平疗效的影响因素进行分析,为临床合理用药提供依据。方法收集 2018年 12月至 2019年 4月西安市精神卫生中心使用奥氮平治疗的精神分裂症病人病例 230例,对其基本信息(性别、年龄、治疗方案)、治疗前及治疗后 1、2、3、4、6周的阳性和阴性症状量表( PANSS)评分和治疗 6周后的副作用量表(TESS)评分进行统计分析。结果在持续治疗的 6周后,痊愈病人 29例( 12.61%)、显著进步 69例( 30.00%)、好转 87例(37.83%),总有效率达 80.43%。治疗前、治疗后 1、2、3、4、6周的 PANSS评分差异有统计学意义;单一用药和联合用药疗效比较,不同性别病人的用药疗效比较,差异无统计学意义;不同年龄段病人的疗效比较,差异有统计学意义。 25例病人出现不良反应现象,不良反应发生率为 10.87%,不良反应发生率相对较低。结论奥氮平治疗精神分裂症起效快,疗效显著,不良反应发生率较低;联合用药不会提高奥氮平的治疗效果,反而会明显增加不良反应的发生率,因此临床上应遵循精神科“单一用药原则”,个体化给药,已达到合理用药的目的。 |
英文摘要: |
Objective To understand the efficacy and adverse reactions of Olanzapine in the treatment of schizophrenia and toguide rational use of Olanzapine in clinic.Methods A total of 230 cases of schizophrenic patients treated with Olanzapine in Xi 'anMental Health Center from December 2018 to April 2019 were collected. The basic information (gender, age, treatment plan), positiveand negative syndrome scale (PANSS) scores before and 1,2,3,4 and 6 weeks after treatment of, treatment emergent symptom scale(TESS) scores 6 weeks after treatment were analyzed statistically.Results After six weeks of continuous treatment, 29 cases (12.61%)were cured, 69 cases (30.00%) were significantly improved, 87 cases (37.83%) were improved, and the total effective rate was 80.43%.There were statistically significant differences in PANSS scores before and after treatment at 1, 2, 3, 4 and 6 weeks. There was no significant difference in the efficacy of single drug and combined drug treatment, and there was no significant difference in the efficacy between genders. There were significant differences in the efficacy of different age groups. There were 25 cases of adverse reactions, theincidence of which was 10.87% and was relatively low.Conclusion Olanzapine is safe and reliable in the treatment of schizophreniaand can be widely used in clinic. Drug combination dose not improve the efficacy of Olanzapine, but significantly increases the incidence of adverse reactions. So in clinical practice, the principle of "single drug use" and individualized drug administration should befollowed to achieve the purpose of rational drug use. |
查看全文
查看/发表评论 下载PDF阅读器 |
关闭 |
|
|
|